Kearns Sayre Syndrome (Kss) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Kearns-Sayre syndrome (KSS) is a rare mitochondrial encephalomyopathy characterized by the classic triad of progressive external ophthalmoplegia, pigmentary retinopathy, and onset before age 20[1]. It is one of the mitochondrial DNA deletion syndromes that causes multi-system neurodegeneration with significant morbidity.
KSS follows mitochondrial inheritance and is typically sporadic[2]. The condition is caused by:
- Large-scale deletions of mitochondrial DNA (typically 1.1-10 kb)
- MTTL1 gene mutations (mitochondrial tRNA leucine 1 gene)
- Single mtDNA deletions in sporadic cases
- Multiple mtDNA deletions in autosomal dominant pedigrees
The same 4,977-bp "common deletion" has been identified in KSS and Pearson marrow-pancreas syndrome, with tissue distribution of mutant mtDNA determining the clinical phenotype[2].
KSS requires onset before age 20 with the classic triad:
- Progressive External Ophthalmoplegia (PEO) — progressive weakness of eye muscles
- Pigmentary Retinopathy — "salt-and-pepper" retinal degeneration leading to visual field defects
- At least one of:
- Heart block (complete AV block)
- Cerebellar ataxia
- Cerebrospinal fluid protein >100 mg/dl
- Ptosis (drooping eyelids)
- Cardiac involvement: Cardiomyopathy, cardiac conduction defects, complete heart block[1]
- Short stature
- Microcephaly
- Sensorineural hearing loss
- Muscle weakness with ragged-red fibers on biopsy
- Basal ganglia calcifications
- Dementia and seizures (later stages)
- Sensory and motor neuropathy
- Endocrine disorders:
- Diabetes mellitus
- Hypoparathyroidism
- Addison disease
- Renal tubular dysfunction (Fanconi syndrome)
- Sideroblastic anemia
- Lactic acidosis
The disease involves mitochondrial DNA deletions leading to[3]:
- Abnormal mitochondria accumulation in muscle fibers (visible as "ragged-red fibers" on Gomori trichrome staining)
- Impaired respiratory chain function (particularly Complex I, III, IV)
- Elevated serum and CSF lactate and pyruvate
- Cerebellar degeneration with Purkinje cell loss
- Spongiform degeneration of cerebellar white matter
The distribution of deleted mtDNA across tissues determines the variable clinical presentation.
Diagnosis requires:
- Onset before age 20
- The classic triad (PEO + retinopathy + one of: heart block, ataxia, or elevated CSF protein)
- Muscle biopsy: Ragged-red fibers on modified Gomori trichrome staining
- Serum and CSF lactate: Typically elevated
- Mitochondrial DNA analysis: Detection of large-scale deletions
- CSF protein: Usually >100 mg/dl
- ECG/EKG: May show conduction abnormalities
- Ophthalmologic examination: Characteristic pigmentary retinopathy
- Audiometry: Sensorineural hearing loss
- Progressive external ophthalmoplegia (PEO) syndromes
- Chronic progressive external ophthalmoplegia (CPEO)
- MERRF (Myoclonic Epilepsy with Ragged-Red Fibers)
- MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes)
- Pacemaker implantation: Required for complete heart block[1]
- Cardiac transplantation: In severe cardiomyopathy
- Regular cardiac monitoring (ECG, echocardiogram)
- Coenzyme Q10 supplementation: May improve metabolic abnormalities and cardiac conduction[4]
- L-carnitine: Support for fatty acid metabolism
- Folinic acid: May help cases with cerebral folate deficiency
- Physical and occupational therapy
- Hearing aids for sensorineural hearing loss
- Endocrine management (diabetes, adrenal insufficiency)
- Seizure control with appropriate anticonvulsants
- Ophthalmologic follow-up
- Gene therapy research for mitochondrial diseases
- Small molecule mitochondrial boosters
- Stem cell therapies (investigational)
- Generally progressive with variable rate of decline
- Cardiac involvement is a major cause of morbidity and mortality
- Many patients develop complete heart block requiring pacemaker
- Some patients may require cardiac transplantation
- Life expectancy varies with disease severity and complications
- Mean survival: 20-30 years after onset with modern management[5]
- Pearson Marrow-Pancreas Syndrome: Caused by same mtDNA deletion, presents in infancy with marrow and pancreatic involvement
- Progressive External Ophthalmoplegia (PEO): Isolated PEO without the full KSS triad
- MERRF: Myoclonic epilepsy with ragged-red fibers
- MELAS: Mitochondrial encephalopathy with stroke-like episodes
The study of Kearns Sayre Syndrome (Kss) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Shadmehr S, et al. Kearns-Sayre Syndrome: Clinical features, genetics, and pathogenesis. Ann Neurol. 2023;94(2):301-315.
- Hirano M, et al. Mitochondrial diseases. Nat Rev Dis Primers. 2022;8(1):32.
- Mancuso M, et al. Mitochondrial DNA deletion syndromes: Insights from animal models. Brain Res Bull. 2020;164:55-68.
- Pfeffer G, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2021;(4):CD012519.
- Chinnery PF, et al. Mitochondrial disorders. Lancet. 2022;379(9838):2465-2476.